Summary & Overview
CPT 80355: Gabapentin Testing on Non-Blood Specimens
CPT code 80355 denotes laboratory testing to measure or detect gabapentin in a patient specimen other than blood. This code captures non-blood drug/toxicology assays used in clinical and outpatient laboratory settings for therapeutic monitoring, compliance verification, or forensic and clinical investigations. Nationally, accurate coding for such assays supports appropriate claims processing, clinical documentation, and surveillance of prescription and illicit use.
Key payers referenced in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and payer coverage perspectives, clinical context for when non-blood gabapentin testing is used, and policy-relevant considerations that affect coding, billing, and laboratory workflows. The content highlights typical sites of service and service type, common modifiers provided in input, and notes where input data were not available.
This summary equips billing professionals, laboratory managers, and policy analysts with a concise reference to CPT code 80355, its clinical purpose, and the payer landscape relevant to national reimbursement and compliance discussions.
Billing Code Overview
CPT code 80355 describes laboratory testing in which a lab analyst measures the amount of or detects the presence of gabapentin in a patient specimen that is not blood. The service type is drug/toxicology testing performed on non-blood specimens (for example, urine or other bodily fluids). The typical site of service is a clinical laboratory or other outpatient laboratory setting where specimens other than blood are submitted for analysis.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves a clinician ordering a urine or other non-blood specimen drug test to confirm presence or concentration of gabapentin when there is clinical concern for adherence, diversion, overdose, or unexpected toxicity. Example: a 45-year-old patient with neuropathic pain on gabapentin presents with increased sedation and dizziness; the clinician obtains a urine specimen for targeted toxicology testing to detect gabapentin and assess recent use. The specimen is collected in the outpatient clinic or urgent care, labeled and sent to the laboratory. The laboratory analyst performs an assay (immunoassay screen with confirmatory testing such as chromatographic methods) on a non-blood matrix (commonly urine, saliva, or oral fluid) to detect and/or quantify gabapentin. Results are reported to the ordering provider and documented in the patient chart; positive or unexpected results may trigger follow-up such as medication reconciliation, patient counseling, or further confirmatory testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician professional interpretation component if separated from the technical lab processing |
90 | Reference (outside) laboratory |